SMS at the peak pollen season
In ILIT after SCIT- 10 000, the median MS in the active group was reduced with 26% at the peak pollen season after treatment compared to before treatment. The placebo group did not improve. There was no change in SS or CSMS within any of the groups and no difference between the active (n=13) or placebo group (n=11) in the SS (p=0.19), MS (p=0.97) or CSMS (p=0.58).
In ILIT de novo- 3000, the placebo group reduced the CSMS and the MS after treatment, while the active group did not improve. There was no difference between the active (n=15) and placebo group (n=18) after treatment in SS (p=0.92), MS (p=0.81) or CSMS (p=0.84). (See Table E2).